Dopamine covalently modifies and functionally inactivates parkin

Author:  ["Matthew J LaVoie","Beth L Ostaszewski","Andreas Weihofen","Michael G Schlossmacher","Dennis J Selkoe"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Inherited mutations in PARK2, the gene encoding parkin, cause selective degeneration of catecholaminergic neurons in the substantia nigra and locus coeruleus of the brainstem, resulting in early-onset parkinsonism. But the role of parkin in common, sporadic forms of Parkinson disease remains unclear. Here we report that the neurotransmitter dopamine covalently modifies parkin in living dopaminergic cells, a process that increases parkin insolubility and inactivates its E3 ubiquitin ligase function. In the brains of individuals with sporadic Parkinson disease, we observed decreases in parkin solubility consistent with its functional inactivation. Using a new biochemical method, we detected catechol-modified parkin in the substantia nigra but not other regions of normal human brain. These findings show a vulnerability of parkin to modification by dopamine, the principal transmitter lost in Parkinson disease, suggesting a mechanism for the progressive loss of parkin function in dopaminergic neurons during aging and sporadic Parkinson disease.

Cite this article

LaVoie, M., Ostaszewski, B., Weihofen, A. et al. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11, 1214–1221 (2005). https://doi.org/10.1038/nm1314

View full text

>> Full Text:   Dopamine covalently modifies and functionally inactivates parkin

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell tr

NKCC1 transporter facilitates seizures in the developing brain